Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
Overview
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.
Full Title of Study: “A Double-Blind, Multicenter, Placebo-Controlled Study of MK0869 in the Treatment of Patients With Major Depressive Disorder”
Study Type
- Study Type: Interventional
- Study Design
- Primary Purpose: Treatment
- Study Primary Completion Date: October 3, 2003
Detailed Description
The duration of treatment is 8 weeks.
Interventions
- Drug: MK0869, aprepitant
- Drug: Comparator: placebo
Clinical Trial Outcome Measures
Primary Measures
- HAMD-17 total score; Tolerability
Secondary Measures
- CGI-I Scale score; Sheehan Disability Scale
Participating in This Clinical Trial
Patients with Major Depressive Disorder
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Provider of Information About this Clinical Study
- Sponsor
References
Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006 Feb 1;59(3):216-23. doi: 10.1016/j.biopsych.2005.07.013. Epub 2005 Oct 24.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.